This week brought a flood of psychedelic research, from DMT's antidepressant potential to psilocybin's effects on clergy. Here's what caught our attention in the labs.
🧠 DMT matches ketamine's antidepressant effects—with longer-lasting benefits
Researchers tested DMT against S-ketamine in stressed mice and found some surprising results:
DMT (10 mg/kg) reduced depression-like behaviors for up to 8 days, while ketamine's effects lasted only 30 hours
Both compounds reversed learned helplessness and reduced escape latency in group-housed mice 24 hours after treatment
DMT also showed anti-anxiety effects that ketamine didn't—reducing stress-induced movement problems and increasing exploration for up to 5 days
Why it matters: DMT's longer-lasting effects could address one of ketamine's biggest limitations as an antidepressant. While ketamine requires frequent dosing, DMT might offer more sustained relief from depression and anxiety symptoms.
Key Findings
🍄 Psilocybin boosts brain plasticity in human neurons
Scientists treated human brain cells (grown from stem cells) with psilocin and watched what happened:
Neurons became more complex and showed increased connectivity after psilocin exposure
The treatment ramped up BDNF (a protein that helps neurons grow) through 5-HT2A receptors
Treated neurons became more excitable and showed enhanced network activity
💡 This cellular evidence may help explain why psilocybin shows promise for treating depression and other brain disorders.
🥈 Top 2% journal 🔗 eLife Journal Article 🗓️ Mar 27 ⛪ Religious leaders report profound spiritual experiences on psilocybin
24 clergy from major world religions received two psilocybin sessions (20-30 mg) with remarkable results:
96% rated the experience among the top 5 most spiritually significant of their lives
42% called it the single most profound experience they'd ever had
79% reported lasting positive changes in their religious practices 16 months later
Most (71%) gained greater appreciation for other religious traditions
💡 Even trained religious professionals found psilocybin experiences spiritually transformative, suggesting the compound's effects transcend specific belief systems.
💊 Standard-dose psilocybin beats placebo for major depression
A meta-analysis of 6 randomized trials involving psilocybin for major depression found:
Standard doses (25 mg) showed strong antidepressant effects compared to controls
Response rates were 2.3 times higher than placebo groups at 2-3 weeks
Remission rates were 3.4 times higher than controls
Low doses (10 mg) showed no benefit over placebo
💡 The dose makes the difference—only higher psilocybin doses showed meaningful antidepressant effects in clinical trials.
🧬 MDMA rewires fear circuits in the brain
Using advanced brain imaging in mice, researchers found MDMA creates lasting changes during fear extinction training:
MDMA increased spine density (connection points between neurons) across prefrontal brain regions
Brain activity patterns changed more rapidly in MDMA-treated mice during extinction learning
The prefrontal cortex became more strongly linked to reduced freezing behavior
💡 MDMA may enhance trauma therapy by physically rewiring fear circuits, not just through psychological effects.
🎯 Blocking a brain enzyme extends ketamine's antidepressant effects
Scientists discovered that suppressing NADPH oxidase-1 (NOX-1) in the brain makes ketamine work longer:
Combining ketamine with a NOX-1 inhibitor prolonged antidepressant effects in treatment-resistant depression model rats
The combination also reduced problematic burst firing in the lateral habenula (a brain region linked to depression)
Knocking down NOX-1 with genetic tools produced similar lasting benefits
💡 Targeting NOX-1 could solve ketamine's biggest clinical problem—its short-lived effects.
🪖 Ibogaine increases brain thickness in veterans with TBI
30 Special Operations veterans with blast-induced brain injuries received ibogaine plus magnesium therapy:
Brain scans showed increased cortical thickness in 11 brain regions after treatment
Participants' predicted brain age decreased by 1.3 years at one month follow-up
8 subcortical brain regions showed significant volume expansion
💡 The brain changes suggest ibogaine may promote healing in traumatic brain injury, though more research is needed.
🎖️ Top 10% journal 🔗 iScience Journal Article 🗓️ Mar 26 Implications
This week's research suggests psychedelics work through multiple biological pathways—from rewiring fear circuits to boosting brain plasticity—with effects that can last days to months. The challenge now is translating these promising lab and early clinical findings into safe, effective treatments for the millions struggling with depression, PTSD, and other mental health conditions.
